Triumvira Immunologics announced new clinical data from its ongoing Phase 1/2 TACTIC-3 clinical trial, evaluating TAC101-CLDN18.2, a novel T cell therapy for Claudin 18.2+ advanced solid tumors. The data, presented in a late-breaking oral presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) 2024, highlight the potential of Triumvira's T cell Antigen Coupler (TAC) technology in targeting challenging cancers.
The TACTIC-3 trial (NCT05862324) is a first-in-human study assessing the safety, recommended Phase II dose (RP2D), pharmacokinetics, and efficacy of TAC101-CLDN18.2 in patients with Claudin 18.2+ solid tumors who have undergone 2 or more prior lines of therapy (1 prior line in patients with pancreatic tumors). The study includes patients with advanced gastric and other solid tumors expressing Claudin 18.2.
Harnessing the Natural Immune System
Robert Williamson, President of Triumvira Immunologics, stated, "Our approach harnesses the body's natural immune system to target challenging cancers like Claudin 18.2+ solid tumors." The TAC technology activates natural T cell functions, offering a unique approach compared to CAR-T and engineered T cell receptor (TCR) therapies. This innovative platform aims to provide clinically safe, effective, and re-dosable cell therapies.
Targeting Claudin 18.2+ Solid Tumors
Claudin 18.2 is a promising tumor-associated antigen expressed in various solid tumors, including gastric, pancreatic, and lung cancers. TAC101-CLDN18.2 is designed to specifically target and eliminate cancer cells expressing this antigen, potentially offering a new treatment option for patients with limited alternatives. The TACTIC-3 trial seeks to address the unmet medical needs in oncology by evaluating this novel therapy in a heavily pre-treated patient population.
Study Design and Objectives
The Phase 1/2 study is designed to determine the optimal dose and evaluate the safety and efficacy of TAC101-CLDN18.2. Key endpoints include assessing the incidence of adverse events, determining the RP2D, and evaluating the anti-tumor activity of the therapy. The trial includes patients with advanced gastric and other solid tumors expressing Claudin 18.2, representing a diverse range of solid tumor types.
